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Abstract
Background: The cardiac surgery–induced systemic inflammatory response may induce postoperative hemodynamic instability
and impairment of renal function. EA-230, a linear tetrapeptide (A-Q-G-V), is derived from the beta chain of the human chorionic
gonadotropin pregnancy hormone. It has shown immunomodulatory and renoprotective effects in several animal models of
systemic inflammation. In phase 1 and phase 2a studies, these immunomodulatory effects were confirmed during human
experimental endotoxemia, and EA-230 was found to have an excellent safety profile.
Objective: The objective of this first in-patient study is to test the safety and tolerability as well as the immunomodulatory and
renoprotective effects of EA-230 in a proof-of-principle design in patients with systemic inflammation following on-pump cardiac
surgery.
Methods: We describe a prospective, randomized, double-blind, placebo-controlled study in which 180 elective patients
undergoing on-pump coronary artery bypass grafting, with or without concomitant valve surgery, are enrolled. Patients will be
randomized in a 1:1 ratio and will receive either EA-230 (90 mg/kg/hour) or a placebo. These will be infused at the start of the
surgical procedure until the end of the use of the cardiopulmonary bypass. The primary focus of this first-in-patient study will
be on safety and tolerability of EA-230. The primary efficacy end point is the modulation of the inflammatory response by EA-230
quantified as the change in interleukin-6 plasma concentrations after surgery. The key secondary end point is the effect of EA-230
on renal function. The study will be conducted in 2 parts to enable an interim safety analysis by an independent data monitoring
committee at a sample size of 60. An adaptive design is used to reassess statistical power halfway through the study.
Results: This study has been approved by the independent competent authority and ethics committee and will be conducted in
accordance with the ethical principles of the Declaration of Helsinki, guidelines of Good Clinical Practice, and European Directive
2001/20/CE regarding the conduct of clinical trials. Results of this study will be submitted for publication in a peer-reviewed
scientific journal. Enrollment of this study commenced in July 2016, and results are expected at the end of 2018.
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Conclusions: This adaptive phase 2 clinical study is designed to test the safety and tolerability of EA-230 in patients undergoing
cardiac surgery. In addition, efficacy end points focused on the effect of the systemic inflammatory response and renal function
are investigated.
Trial Registration: ClinicalTrials.gov NCT03145220; https://clinicaltrials.gov/ct2/show/NCT03145220 (Archived by WebCite
at http://www.webcitation.org/74JPh8GNN)
International Registered Report Identifier (IRRID): DERR1-10.2196/11441
(JMIR Res Protoc 2019;8(2):e11441)  doi: 10.2196/11441
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Introduction
Background
The systemic inflammatory response syndrome is characterized
by a dysregulated inflammatory reaction in response to
conditions such as a severe infection, trauma, and major surgery
[1,2]. Although activation of the immune system is essential, a
too-pronounced systemic inflammatory response may result in
failure of 1 or more organ systems and is associated with
morbidity and mortality rates up to 30% [3,4]. Development of
acute kidney injury (AKI) represents an early and common
manifestation of inflammation-induced organ failure [5-7].
During cardiac surgery, multiple insults, including sternotomy,
application of cardiopulmonary bypass (CPB), and aortic
cross-clamping are well known to contribute to a systemic
inflammatory response [8-11]. The extent of this response is
directly associated with impaired patient outcome, as elevated
postoperative levels of interleukin (IL)-6 correlate with adverse
outcomes and mortality [5,12]. Furthermore, this inflammatory
response is believed to play a central role in the pathogenesis
of AKI following cardiac surgery [13,14]. In addition, renal
impairment is, in turn, independently associated with adverse
outcome and impaired patient survival [15,16].
Immunomodulation
Immunomodulatory strategies until now have failed to
demonstrate clear beneficial effects in cardiac surgery patients
[17]. For example, large trials on the use of high-dose
corticosteroids did not improve overall patient outcome in
cardiac surgery patients [18,19], although positive effects on
respiratory variables in selected patient groups may be present,
as found in post hoc analyses [19]. Nonspecific
anti-inflammatory effects and the broad spectrum of side effects
of these interventions may have contributed to the lack of overall
beneficial effects of these compounds. As a result, current
strategies consist of supportive treatment, and novel strategies
aimed to attenuate the exaggerated proinflammatory response
remain highly warranted.
Of interest, pregnancy is associated with an immune-tolerant
adaptation of the immune system, necessary to facilitate the
symbiosis of 2 major histocompatibility complex incompatible
individuals [20]. Likely related to this effect, a remarkable
improvement of several immune-mediated inflammatory
diseases is observed during pregnancy [21-23]. Nevertheless,
pregnant women are eminently capable of combating infections
and often produce antibodies against paternal alloantigens of
the fetus, demonstrating that they are fully immunocompetent.
These features are suggestive of a selective modulation of the
immune system in such a way that harmful immune processes
to mother and fetus are suppressed, whereas beneficial immune
processes remain unaffected. In this context, an array of
oligopeptides related to the primary structure of the human
chorionic gonadotropin (hCG) pregnancy hormone was designed
and evaluated in experimental animal models of systemic
inflammation [24-29]. Of the evaluated oligopeptides, the linear
tetrapeptide (sequence: A-Q-G-V), now named EA-230, was
shown to exert immunomodulatory effects and to protect against
organ failure and associated mortality [25,26,28,30,31]. In
particular, the administration of EA-230 resulted in renal
function preservation, for example, in ischemia-reperfusion and
kidney transplant models [30,31]. It is probable that the profound
effects of pregnancy on renal function through increasing renal
flow and subsequently increasing glomerular filtration rate
(GFR) are causal to these findings [32]. Phase 1 safety studies
of EA-230 showed that intravenous administration is well
tolerated and has an excellent safety profile [33]. In a phase 2a
study during human experimental endotoxemia, a model of
controlled systemic inflammation induced by the administration
of endotoxin, no safety concerns emerged. Furthermore, subjects
treated with the highest dose of EA-230 (90 mg/kg/hour)
resulted in less flu-like symptoms, attenuated development of
fever, and reduced levels of proinflammatory mediators (among
others IL-6 and IL-8) when compared with placebo-treated
endotoxemia subjects [34].
Objectives
A proof-of-principle study is now warranted to (1) investigate
the safety profile of EA-230 in patients, (2) investigate whether
EA-230 is able to modulate the systemic inflammatory response
in patients, and (3) explore whether this translates into a clinical
benefit in terms of prevention of organ dysfunction, in particular,
renal injury. In this paper, we describe the design of a
double-blind, placebo-controlled, randomized, adaptive phase
2 study with EA-230 in patients undergoing elective on-pump
cardiac surgery.
Methods
Design and Setting
This study is a single-center, prospective, double-blind,
placebo-controlled, randomized, single-dose phase 2 study. It
has an adaptive design to evaluate the safety and
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immunomodulatory effects of EA-230 in patients undergoing
on-pump cardiac surgery for coronary artery bypass grafting
(CABG) with or without concomitant valve surgery. A total of
180 eligible patients are planned for inclusion and will be
randomized to receive either active or placebo treatment in a
1:1 ratio. The study will be conducted in a tertiary hospital, the
Radboud University Medical Center, Nijmegen, the Netherlands.
This is the first-in-patient safety and tolerability study, of which
the primary efficacy objective is to assess the
immunomodulatory effects of EA-230. The key secondary
efficacy end point is the effect of EA-230 on renal function.
With regard to safety in this first-in-patient study, the study will
be conducted in 2 parts. In the first part, 60 patients (40-50
low-risk patients) will be included (see Textboxes 1 and 2 for
details) followed by an independent safety analysis by the data
monitoring committee (DMC). Patient enrollment will only
continue if no safety concerns are raised, and more high-risk
patients will be included.
In addition, an adaptive design is used to re-evaluate the
statistical power and group size of the study using patient data
obtained during the first half of the study. This study is described
in accordance with the Standard Protocol Items:
Recommendations for Interventional Trial guidelines [35] and
registered at ClinicalTrials.gov (identifier: NCT03145220).
Study Objectives
Primary Objectives
The primary objectives of the study are to (1) assess the safety
and tolerability of EA-230 in patients undergoing on-pump
cardiac surgery (related to safety) and (2) assess the
immunomodulatory effects of EA-230 in patients with systemic
inflammation following on-pump cardiac surgery (related to
efficacy).
Key Secondary Objective
The key secondary objective is to assess the effects of EA-230
on changes in renal function (GFR).
All end points, including other explorative efficacy end points,
are described in Table 1.
Textbox 1. Inclusion criteria.
1. Coronary artery disease, scheduled for elective on-pump coronary artery bypass grafting surgery with or without concomitant valve surgery
2. Written informed consent to participate in this study before any study-mandated procedure
3. Patients aged above 18 years, both male and female
4. Patients have to agree to use a reliable form of contraception with their partners from study entry until 3 months after study drug administration
Textbox 2. Exclusion criteria.
1. Immune compromised
• Solid organ transplantation
• Known HIV
• Pregnancy
2. Use of immunosuppressive drugs (list provided in Web-based supplementary material; see Multimedia Appendix 1)
3. Nonelective/emergency surgery
4. Hematological disorders
• Known disorders from myeloid and/or lymphoid origin
• Leucopenia
5. Known hypersensitivity to any excipients of the drug formulations used
6. Treatment with investigational drugs or participation in any other intervention clinical study within 30 days before study drug administration
7. Inability to personally provide written informed consent (eg, for linguistic or mental reasons)
8. Known or suspected of not being able to comply with the study protocol
Additional exclusion criteria to select low-risk patients (for the first 60 patients only)
1. EuroSCORE II >4
2. Renal function impairment: serum creatinine >200 µmol/L
3. Liver function impairment: alanine aminotransferase/aspartate aminotransferase >3 times above upper level of reference range
4. Left ventricular dysfunction: ejection fraction <35%
5. Coronary artery bypass grafting procedure with concomitant valve surgery
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Table 1. End points.
PeriodCategories and measures
Main category
Safety and tolerability
Signing of informed consent form
to day 90
(Serious) adverse events
First 24 hours of intensive care unit
(ICU) admission
Vital signs (heart rate and blood pressure)
Day −1 to day +1Laboratory parameters (hemoglobin, hematocrit, leukocytes, thrombocytes, leukocyte differential blood
count, sodium, potassium, creatinine, urea, alkaline phosphatase, alanine aminotransferase, aspartate
aminotransferase, gamma glutamyl transferase, creatine kinase, bilirubin, and C-reactive protein)
Efficacy
Surgery day to day 1Primary: Effect of EA-230 on the inflammatory response quantified by the change in ILa-6 plasma concen-
tration over time (AUCb).
Day −1 to day +1Key secondary: Effect of EA-230 on GFRc quantified by plasma clearance of iohexol (iGFRd)
Explorative category
Inflammatory
Surgery day to day 1Effect of EA-230 on the inflammatory response quantified by the change in plasma concentrations
over time of IL-6, IL-8, IL-10, tumor necrosis factor-α, IL-1 receptor antagonist, monocyte chemoat-
tractant protein-1, macrophage inflammatory protein 1 (MIP1)e-α, MIP1-β, vascular cell adhesion
molecule, intercellular adhesion molecule, and IL-17a
Day −1 to day +1Effect of EA-230 on leukocyte kinetics quantified by change of total cell counts over time
First 24 hours of ICU admissionEffect of EA-230 on changes in body temperature in degree Celsius over time
First 24 hours of ICU admissionEffect of EA-230 on required insulin infusion rates
Renal
Day −1 and day +1Effect of EA-230 on GFR estimated by modification of diet in renal disease calculation
Surgery to day +1Effect of EA-230 on GFR measured by endogenous creatinine clearance using urine and plasma crea-
tinine
Day −1 to day +1Effect of EA-230 on plasma creatinine and proenkephalin
Surgery to day +1Effect of EA-230 on changes in urine output
Surgery to day +1Effect of EA-230 on changes in urinary renal damage markers over time of kidney injury marker-1,
neutrophil gelatinase–associated lipocalin, L-fatty acid–binding protein, tissue inhibitor metallopro-
teinase-2 and insulin-like growth factor binding protein-7, urinary IL-18, and N-acetyl-β-D-glu-
cosaminidase
Surgery to day +1Effect of EA-230 on changes in urea, sodium, creatinine, and albumin in urine over time
Surgery to day 90Modulation in need for and duration of renal replacement therapy
Surgery to day 90Modulation in incidence of different stages of AKIf according to the RIFLEg criteria
Cardiovascular
First 24 hours of ICU admissionModulation in vasopressor use expressed as inotropic score: (dopamine dose × 1 μg/kg/min) + (dobu-
tamine dose × 1 μg/kg/min) + (adrenaline dose × 100 μg/kg/min) + (noradrenaline dose × 100 μg/kg/min)
+ (phenylephrine dose × 100 μg/kg/min) + (vasopressin (mUnits/kg/min) × 10,000) + (milrinone × 10
mcg/kg/min) [36]
First 24 hours of ICU admissionEffect of EA-230 on use of fluid therapy and fluid balance
Surgery to end of hospital stayEffect of EA-230 on creatine kinase and troponine T plasma concentration
Surgery to end of ICU admissionEffect of EA-230 on thorax drain production
Surgery to end of ICU admissionPulmonary: Effect of EA-230 on alveolar-arterial gradient O2 gradient
General outcome
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PeriodCategories and measures
First 24 hours of ICU admissionEffect of EA-230 on change in SOFAh score over time
Surgery to ICU admissionEffect of EA-230 on APACHEi IV score at ICU admission
Signing of informed consent form
to day 90
Effect of EA-230 on major clinical adverse events within 90 days (stroke, myocardial infarction,
rethoracotomy, hospital readmission, and pleural and/or pericardial puncture)
Surgery to day 90Effect of EA-230 on length of stay on ICU
Surgery to day 90Effect of EA-230 on length of hospital stay
Surgery to day 90Effect of EA-230 on 28 and 90 days mortality
Pharmacokinetics of EA-230
10 min before start and stop of CPBjPeak blood plasma levels of EA-230
During EA-230 administration to 6
hours after stoppage
Blood plasma levels of EA-230, AUC, maximal concentration, terminal half-life, clearance, and volume
of distribution for a limited number of patients receiving active medication (n=15)
aIL: interleukin.
bAUC: area under the curve.
cGFR: glomerular filtration rate.
diGFR: glomerular filtration rate measured by plasma clearance of iohexol.
eMIP1: macrophage inflammatory protein.
fAKI: acute kidney injury.
gRIFLE: risk, injury, failure, loss of kidney function, and end-stage kidney disease classification.
hSOFA: sepsis-related organ failure assessment score.
iAPACHE: acute physiology and chronic health evaluation.
jCPB: cardiopulmonary bypass.
Patient Selection or Eligibility
All adult patients (aged >18 years) scheduled for elective
on-pump CABG procedure with or without concomitant valve
surgery will be screened for eligibility; see Textboxes 1 and 2
for an overview of all inclusion and exclusion criteria.
Recruitment
Figure 1 depicts a schematic flowchart of patient recruitment
and randomization.
All patients scheduled for elective CABG surgery will be
included in a screening log and informed through a detailed
informative brochure. After screening for inclusion and
exclusion criteria, eligible patients will be personally consulted,
and a final inclusion and exclusion check will be performed.
After obtaining written informed consent, patients will be
enrolled into the study.
Randomization and Stratification
On the morning of surgery, patients will be randomized by
nonblinded independent study personnel for active or placebo
treatment. Study personnel will use Good Clinical Practice–
approved data management software (Castor EDC, Amsterdam,
the Netherlands) in this process. The Castor system applies a
stratified randomization to ensure equal distribution between
active and placebo treatment of patients with known risk factors
for adverse outcomes. Moreover, 3 strata will be included: (1)
a CABG procedure with or without concomitant valve surgery;
(2) preoperative renal function with an estimated GFR of ≤30,
31 to 90, and >90 mL/min/1.73 m2; and (3) a EuroSCORE II
of <4 or ≥4 [37].
Blinding
Double-blind conditions will be maintained for all patients, the
attending physicians, and the medical study team personnel
involved in all blinded study procedures, data collection, and/or
data analyses. Nonblinded study personnel not involved in any
other study procedures will prepare the study medication.
Infusion systems and solutions for active and placebo treatment
are identical in appearance and texture. The interim safety
analysis will be performed by an independent data safety and
monitoring board in an unblinded fashion. If it is decided that
the study can be continued, all study personnel remain blinded.
Unblinding will be authorized by the sponsor after completion
of the study, performance of a blinded data review, and locking
of the database. A sealed code break envelope is present in case
emergency unblinding should be necessary.
Study Intervention
Intravenous infusion of EA-230, 90 mg/kg/hour, or placebo,
will be initiated at the moment of the first surgical incision using
an automated infusion pump. Infusion rate is 250 mL/hour, and
infusion will be continued until cessation of the CPB or after 4
hours of continuous infusion, whichever comes first.
EA-230 formulation is packed in sterile 5-mL glass vials,
containing 1500 mg/vial, dissolved in water for injection at a
final concentration of 300 mg/mL with an osmolality of 800 to
1000 mOsm/kg. The placebo formulation consists of sodium
chloride diluted in water for injection in identical sterile 5-mL
glass vials containing 29 mg/mL to reach a solution with an
identical osmolality. EA-230 and placebo will be prepared for
continuous intravenous infusion with an osmolality of <400
mOsm/kg by adding the appropriate amount of EA-230 or
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placebo to 1000 mL normal saline under aseptic conditions.
Placebo and active treatment vials, manufactured by HALIX
BV (Leiden, the Netherlands), will be provided by the sponsor.
Outcome Measures
An overview of the study procedures from inclusion criteria
until end of follow-up is depicted in Figure 2. A detailed
overview of all outcome measures is also provided in Table 1.
Figure 1. Study flowchart. Overview of patient recruitment, randomization, and population analysis procedures from screening to follow-up. CABG:
coronary artery bypass grafting.
Figure 2. Timeline of study procedures. CPB: cardiopulmonary bypass; ICU: intensive care unit; iGFR: glomerular filtration rate measured by plasma
clearance of iohexol; OR: Operating Room.
JMIR Res Protoc 2019 | vol. 8 | iss. 2 | e11441 | p. 6http://www.researchprotocols.org/2019/2/e11441/
(page number not for citation purposes)
van Groenendael et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Primary End Point
The primary focus is the safety and tolerability of EA-230. This
is defined by the combination of several safety measurements:
the incidence and severity of serious adverse events (SAEs) and
serious unexpected suspected adverse reactions (SUSARs), the
course of vital signs (heart rate and blood pressure), and the
course of routine laboratory parameters. Vital signs and routine
laboratory parameters will be registered during the first
postoperative day when patients are admitted to the intensive
care unit. Safety data will be collected from inclusion in the
study until 90 days after the administration of the study drug.
The primary efficacy end point is the modulation of the
inflammatory response by EA-230. This will be quantified by
the difference in the area under the curve (AUC) plasma IL-6
levels over time from the start of the cardiac procedure until the
first postoperative day compared with placebo. Plasma samples
will be collected preincision (baseline) at the start of CPB; at
0, 2, 4, and 6 hours after cessation of the CPB; and on the
morning of the first postoperative day.
Key Secondary End Point
Modulation of changes in renal function by EA-230 is defined
by changes in the GFR measured before surgery and on the
morning of the first postoperative day. For the determination
of the GFR, an intravenous bolus of 5 mL iohexol will be
administered, and plasma samples will be collected in the
following 4 hours. On the day before surgery: 90 and 240 min
after iohexol administration and on the postoperative day: 90,
180, and 240 min after iohexol administration. A plasma
disappearance curve of iohexol will be constructed to calculate
the iohexol GFR (iGFR) according to the methods described
by Delanaye et al [38].
All other secondary efficacy end points are exploratory. Data
for both parts of the study will be combined to assess both the
safety and efficacy of the primary and secondary end points.
Sample Size Calculation
The primary efficacy end point, AUC of plasma IL-6 levels
over time, was used for the power calculation. In the preceding
clinical phase 2a study with EA-230, during experimental
endotoxemia in healthy volunteers, EA-230 (90 mg/kg/hour)
attenuated AUC plasma IL-6 levels by 48% compared with
placebo. This first-in-patient proof-of-principle study is powered
on a 30% reduction in AUC IL-6, which is deemed a relevant
immunomodulatory effect. For the statistical dispersion, AUC
IL-6 data from a previous CABG surgery study conducted in
the same institute were used (mean 816 pg/mL/hour, SD of 520
pg/mL/hour) [39]. To correct for the nonparametric distribution
of these data, the calculated sample size is increased by 15%
[40]. With a 2-sided alpha of .05 and a power of 80% (beta of
.2), a group size of 82 patients per treatment arm is required.
However, selection of low-risk patients in the first part of the
study with an expected less pronounced inflammatory response
may result in an increased SD of AUC IL-6 in the overall study,
and therefore, loss of study power. Hence, the sample size
should be adjusted accordingly. In consultation with an
independent statistician, a sample size of 90 patients per
treatment arm was deemed sufficient to compensate for this
loss in power. Using an adaptive design, sample size will be
re-evaluated, and possible early efficacy will be assessed
halfway through the study, when 90 patients have been included.
A partially unblinded independent statistician and member of
the DMC will perform these analyses. For the re-evaluation of
the sample size, the pooled SD of the AUC plasma IL-6 levels
of the first 90 patients enrolled will be calculated and used to
compare with the original sample size according to the method
described by Proschan [41]. To demonstrate possible early
efficacy, the approach for alpha-spending according to
O’Brien-Fleming will be used [42]; a t test will be performed
on the collected data with the following alpha
(α1(t*)):α1(t*)=2−2φ(Z α/2/√t*) where t* represents the
information fraction (t*=0.5 × original sample size/new sample
size). If P<α1(t*), the study will be stopped because of early
demonstrated efficacy. When no significant differences are
found during this interim analysis, the study will continue. For
final analysis, an adjusted alpha will be used, corrected for alpha
spending.
Statistical Analysis
The safety parameters will be listed and summarized
descriptively according to treatment. No statistical testing on
safety end points will be performed. The statistical analysis plan
for efficacy end points will be signed before database lock and
is provided as online supplementary material (see Multimedia
Appendix 2). Data will be presented as mean and SD or SE of
the mean or median and interquartile range and analyses
performed, depending on their distribution. The primary efficacy
end point, the difference in IL-6 plasma concentrations over
time (AUC IL-6 plasma levels) between treatment groups, will
be analyzed using an unpaired Student t test or Mann-Whitney
U test (the latter if data are not normally distributed). In a
secondary analysis, the AUC IL-6 plasma levels between
treatment groups will also be compared using 2-way analysis
of variance (ANOVA; interaction term, on log-transformed data
if data are not normally distributed). Differences in the key
secondary efficacy end point iGFR between treatment groups
over time will be analyzed using 2-way ANOVA, as described
above. All other data will be analyzed using unpaired Student
t tests or Mann-Whitney U tests for continuous data, 2-way
ANOVA for continuous data over time as described above, and
chi-square tests for categorical data. A 2-sided P value <.05 is
considered significant. For the primary end point, a P value
corrected for alpha spending will be used as described earlier.
Statistical analyses will be performed using IBM SPSS (IBM,
Armonk, NY, USA) and GraphPad Prism (GraphPad Software,
La Jolla, CA, USA).
Withdrawal of Study Patients
Patients may leave the study at any time, for any reason, and
without any consequences. The investigator can decide to
withdraw a patient from the study for urgent medical reasons
or in case of inability to comply with the study protocol.
There is a likely possibility that patients enrolled in the study
have their cardiac surgery rescheduled as a result of urgent
intervening surgeries or because they meet an exclusion criterion
shortly before the start of surgery. Therefore, patients who are
withdrawn from the study before investigational medicinal
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product administration will be replaced and thus will not be
included in any analysis.
Different Populations to be Analyzed
Intention-to-Treat Population
The intention-to-treat (ITT) population includes all patients who
were randomized and received study treatment, irrespective of
satisfying other end point criteria. This population will be used
for the analysis of safety and tolerability and all other primary
and secondary end points.
Per-Protocol Population
Analysis of the per-protocol (PP) population will be used as a
supplement to the ITT analysis and will be performed for all
end points except safety-related end points. The PP includes all
ITT patients who have not been excluded from analysis for
major protocol deviations.
Pharmacokinetic Population
Sampling for pharmacokinetic (PK) population analysis will be
performed in 30 patients. As EA-230/placebo ratio is 1:1, the
PK population will include a subset of approximately 15 patients
who received EA-230. For this full PK evaluation, additional
blood samples will be obtained during infusion of EA-230 until
6 hours after cessation of administration.
Subgroup Analyses
Subgroup analyses will be performed on the following
predetermined preoperative randomization strata: (1) CABG
with or without concomitant valve surgery; (2) preoperative
renal function with an estimated GFR of ≤30, 31 to 90, and >90
mL/min/1.73 m2; and (3) EuroSCORE II of <4 or ≥4.
Safety Considerations
Adverse Events
All adverse events will be judged by the investigators with
regard to severity (mild, moderate, or severe) according to
Common Terminology Criteria for Adverse Events guidelines
4.030 [43] and their perceived relation to the study drug
(definitely, probably, possibly, or unrelated/unlikely to be
related). SAEs or SUSARs include death, life-threatening
disease, persistent and/or significant disability and/or incapacity,
and hospitalization and/or prolongation of inpatient
hospitalization.
The investigator will report all SAEs and SUSARs to the
sponsor without undue delay after obtaining knowledge of the
events. Monitoring and re-evaluation of the SAE/SUSAR and
its relation to the study drug will subsequently be performed by
an independent medical doctor with the independent Contract
Research Organization QPS (Groningen, the Netherlands) and
reported to the Central Committee on Research Involving
Human Subjects (CCMO, The Hague, The Netherlands) within
a maximum period of 15 days (or 7 days when the event is life
threatening or results in death) and to the independent ethics
committee of the Radboud University Nijmegen Medical Center
(CMO, Arnhem-Nijmegen, the Netherlands).
Data Monitoring Committee
An independent DMC, consisting of 3 expert members,
including 1 biostatistician, will assess safety of the study drug.
The first DMC meeting will be held on completion of the first
part of the study that includes 40 to 50 low-risk patients. During
this interim safety analysis, inclusion will be paused, and an
extensive partially unblinded assessment of (S)AEs, vital signs,
and routine laboratory parameters will be performed. Inclusion
of patients in the study will only continue if no safety concerns
are raised by the DMC. A second meeting will be held after 90
patients have been enrolled (including higher risk patients) to
reassess all safety parameters. At this point, the DMC will advise
on the continuation or termination of the study.
Ethical Considerations
The regional and central independent ethical committee, CMO
Arnhem-Nijmegen, and the CCMO, respectively, have approved
the study protocol, amendments, informed consent, and all other
study-relevant written information for the patients. The study
will be conducted in accordance with the ethical principles of
the Declaration of Helsinki ICH E6(R1), the Medical Research
Involving Human Subjects Act, guidelines of Good Clinical
Practice, and European Directive (2001/20/CE). Informed
consent will be obtained before any study-specific procedures
are performed. Substantial amendments will be provided to the
CMO for approval. Nonsubstantial amendments will be provided
to the CMO for notification.
Data Quality Assurance and Publication
Data will be handled confidentially and anonymously. The study
site maintains source documentation and is responsible for
accurate data entry in electronic case report form. The Good
Clinical Practice–certified data capture system Open Clinica
(Waltham, MA, USA) was used in this process. Blinded study
personnel are provided with an individual username and
password with complete traceability. Quality assurance, data
management with full data validation and monitoring of all
source documents, study procedures, study data, SAEs, and
SUSARs will be performed by the independent Contract
Research Organization QPS. The database will be locked after
completion of the data review, resolutions to all queries, and
the signing of the statistical analysis plan. Following database
lock, a study patient identification code list (provided by the
Castor data management system, Amsterdam, the Netherlands)
will be used to link the stratified interventional treatment (active
or placebo) to the patient. Data and body material will be kept
in secure storage at the intensive care research department and
is accessible by study personnel only. The handling of patient
data in this study complies with the Dutch Personal Data
Protection Act (in Dutch: Wet Bescherming Persoonsgegevens).
The principal investigator and the subinvestigators will write
the manuscript that will be submitted for publication in a
peer-reviewed scientific medical journal after completion of the
study, irrespective of results.
Patient and Public Involvement
Patients and the public were not involved in the design and/or
the conduct of the study protocol. Study outcome will be
disseminated to all study participants individually. The burden
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of the intervention was assessed by the independent ethics
committees CMO and CCMO, which include laymen members.
Results
Enrollment of this study commenced in July 2016, and results
are expected at the end of 2018.
Discussion
General
To evaluate the safety, immunomodulatory, and renoprotective
effects of EA-230, we designed this single-center, double-blind,
randomized, placebo-controlled adaptive phase 2 study in
patients undergoing on-pump cardiac surgery. In this study
primarily focused on safety, we will also assess the
immunomodulatory effects of EA-230. Our key secondary
objective is to investigate whether EA-230 prevents a decrease
in renal function (which is possibly related to its
immunomodulatory effects) in this patient population. Patients
undergoing on-pump cardiac surgery represent an ideal study
population to evaluate the effects of EA-230 on the systemic
inflammatory response in a proof-of-principle study. These
cardiac surgery procedures are highly standardized and have a
well-characterized sequence of inflammatory insults: release of
Danger-Associated Molecular Pathways as a result of tissue
damage during incision and sternotomy, leukocyte activation
induced by the use of the extracorporeal circuit, ischemia-
reperfusion damage following aortic cross-clamping and
subsequent declamping, and translocation of endotoxins because
of increased gut permeability [8-11]. Due to the elective timing
of these insults, the moment of activation of the immune system
is well defined, and the following inflammatory response during
and after surgery follows a relatively homogenous pattern.
Furthermore, the inflammatory response is clinically relevant,
as inflammatory mediators IL-6 and IL-8 have been shown to
be key orchestrators of the systemic inflammatory response
following cardiac surgery and are associated with postoperative
adverse outcome, including the occurrence of AKI and long-term
mortality [5,12,44]. As EA-230 has attenuated IL-6 and IL-8
in earlier work [34], it has the potential to modulate release of
these specific mediators that are associated with organ failure
in cardiac surgery patients.
Design
The inclusion and exclusion criteria of this study are not overly
restrictive to facilitate enrollment and to increase
generalizability. Although the inflammatory response is
relatively comparable among cardiac surgery patients, these
permissive criteria might influence study results because patients
with known preoperative risk factors may develop a more
pronounced inflammatory response and/or have a worse
outcome. However, in a randomized study such as this, these
interpatient differences are likely to be equally divided between
treatment and placebo groups. Nevertheless, we used a stratified
randomization procedure to optimize group balance. In addition,
3 major preoperative determinants for outcome, namely baseline
renal function, EuroSCORE II [37], and CABG with or without
valve surgery were used to ensure equal distribution between
groups of patients with known risk factors.
The 2-part study design facilitates an extensive safety interim
analysis by the DMC after the first part and limits potential risks
for patients. It also ensures efficient assessment of efficacy by
combining data from both parts for all safety and efficacy
analyses. Furthermore, with the use of an adaptive design, the
trial sample size can be adjusted halfway through the trial by
conducting a new power calculation using the variation of IL-6
concentrations of obtained data of the first half of the study,
this way guaranteeing adequate statistical power. The use of
such an adaptive design has recently been recommended for the
design of clinical studies such as this study [45].
To date, no side effects attributed to EA-230 have been
observed, which is in sharp contrast to other immunomodulatory
drugs. This may be because of the fact that EA-230 is an
endogenous, immunological active breakdown product of the
pregnancy hormone beta hCG. In addition, the fact that the
tolerant immune phenotype during pregnancy is not
accompanied with complications related to immunosuppression
suggests that targeting this pathway may be of more benefit
than the use of other immunomodulatory therapies.
Evaluation of the effects of EA-230 on renal function is of
specific interest in this study for several reasons. First, EA-230
exerted potent renal protective effects in animal studies. Second,
a significant proportion of these patients suffer from
postoperative renal injury [13,14], which is, in turn, related to
their clinical outcome [15,16]. This study is unique in terms of
accurate assessment of renal function because a gold standard
method to measure GFR is used, instead of estimating GFR
based on serum creatinine. Although it is well established that
serum creatinine and urine output are suboptimal parameters to
assess acute deterioration of renal function, they remain to be
the most commonly used markers to diagnose AKI clinically
and in research settings. Creatinine is unreliable because it is a
late marker and is influenced by muscle mass, fluid shifts,
immobilization and is partially, but actively, secreted by the
kidneys [46-48]. The iGFR method has proven to be as reliable
as the inulin clearance (with an R2 of 0.96 [49]) and accurately
detects even minor changes [38,50]. Therefore, clinically
significant changes in GFR can be reliably assessed in this study.
These renal function measurements have not been performed
in any large cardiac surgery trial to date and will substantially
improve the validity of the data and quality of this study. As a
potential downside, the iohexol method does require trained
personnel in the collection of multiple blood samples to create
a plasma decay curve. As a result of this labor-intensive process,
iGFR measurements will be performed only twice in this study:
preoperatively, representing a baseline measurement and on the
morning of the first postoperative day. As discussed earlier,
conventional renal function markers are late and unreliable.
Therefore, little is known about the exact postoperative course
of renal function deterioration and/or decrease in GFR. As such,
there is a chance that the single postoperative iGFR
measurement could fail to detect a decrease in GFR following
on-pump cardiac surgery.
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A limitation of this study is the dose of EA-230. Only one dose
is used, based on the fact that only the highest dose was effective
in terms of modulating the immune response in the previous
experimental human endotoxemia study [34]. As a result, it will
remain unknown whether similar efficacy in patients can be
attained using a lower dose or higher efficacy can be achieved
using a higher dose. Furthermore, whether the use of the
artificial extracorporeal circulation affects EA-230’s
pharmacokinetics or pharmacodynamics is unknown. Along
these lines, the fluid balance shift in patients undergoing cardiac
surgery may alter distribution of EA-230, with nontherapeutic
plasma concentrations as a possible result.
Summary
The EASI Study is a double-blind, randomized, placebo-
controlled phase 2 study of EA-230 in 180 patients undergoing
on-pump cardiac surgery. It applies stratification and has an
adaptive study design. Apart from safety and tolerability, it is
designed to examine the immunomodulatory and renal protective
effects of EA-230 in patients with systemic inflammation.
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